Free Trial

LivaNova (LIVN) Stock Price, News & Analysis

-0.73 (-1.19%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
540,954 shs
Average Volume
629,275 shs
Market Capitalization
$3.28 billion
P/E Ratio
Dividend Yield
Price Target

LivaNova MarketRank™ Stock Analysis

Analyst Rating
2.40 Rating Score
9.3% Upside
$66.20 Price Target
Short Interest
4.86% of Shares Sold Short
Dividend Strength
News Sentiment
1.21mentions of LivaNova in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From $2.59 to $2.88 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

716th out of 921 stocks

Electromedical Equipment Industry

15th out of 19 stocks

LIVN stock logo

About LivaNova Stock (NASDAQ:LIVN)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

LIVN Stock Price History

LIVN Stock News Headlines

LivaNova: Focus Is Paying Off
LivaNova Reports First-Quarter 2024 Results
LivaNova PLC Q1 2024 Earnings Preview
LivaNova PLC
LivaNova to Announce First-Quarter 2024 Results
See More Headlines
Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Electromedical equipment
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$17.55 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.15 billion
Cash Flow
$4.26 per share
Book Value
$23.72 per share


Free Float
Market Cap
$3.32 billion
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Alex Shvartsburg (Age 53)
    Chief Financial Officer
    Comp: $852.2k
  • Ms. Trui Hebbelinck (Age 52)
    Chief Human Resources Officer
    Comp: $731.41k
  • Mr. Vladimir A. Makatsaria (Age 51)
    CEO & Director
  • Mr. Badri Amurthur
    Chief Technology Officer
  • Lindsey Little
    Senior Director of Investor Relations
  • Mr. Michael D. Hutchinson (Age 53)
    Senior VP, Chief Legal Officer & Company Secretary
  • Deanna Wilke
    Vice President of Corporate Communications
  • Mr. Matthew Joseph Dodds III
    Senior Vice President of Corporate Development & IT
  • Dr. Bryan D. Olin Ph.D. (Age 57)
    Senior VP & Head of Product Development - Neuromodulation
  • Mr. Ryan Miller
    President of Advanced Circulatory Support

LIVN Stock Analysis - Frequently Asked Questions

Should I buy or sell LivaNova stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" LIVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIVN, but not buy additional shares or sell existing shares.
View LIVN analyst ratings
or view top-rated stocks.

What is LivaNova's stock price target for 2024?

5 brokers have issued twelve-month target prices for LivaNova's shares. Their LIVN share price targets range from $52.00 to $80.00. On average, they expect the company's stock price to reach $66.20 in the next twelve months. This suggests a possible upside of 9.3% from the stock's current price.
View analysts price targets for LIVN
or view top-rated stocks among Wall Street analysts.

How have LIVN shares performed in 2024?

LivaNova's stock was trading at $51.74 at the beginning of the year. Since then, LIVN shares have increased by 17.0% and is now trading at $60.5450.
View the best growth stocks for 2024 here

When is LivaNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024.
View our LIVN earnings forecast

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings results on Wednesday, May, 1st. The company reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.28. The firm earned $294.90 million during the quarter, compared to analysts' expectations of $278.17 million. LivaNova had a positive trailing twelve-month return on equity of 13.59% and a negative net margin of 2.68%. The business's revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.43 earnings per share.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova issued an update on its FY24 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of $3.05-3.15 for the period, compared to the consensus earnings per share estimate of $3.00.

What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Damien McDonald has an approval rating of 77% among the company's employees.

What other stocks do shareholders of LivaNova own?
Who are LivaNova's major shareholders?

LivaNova's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.38%), Redmile Group LLC (1.92%), Allspring Global Investments Holdings LLC (1.46%), Allspring Global Investments Holdings LLC (1.46%), Magnetar Financial LLC (1.39%) and Paradice Investment Management LLC (0.78%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald and Daniel Jeffrey Moore.
View institutional ownership trends

How do I buy shares of LivaNova?

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIVN) was last updated on 5/21/2024 by Staff

From Our Partners